Evonik Industries AG (EVKIF)

OTCMKTS · Delayed Price · Currency is USD
17.30
-0.25 (-1.42%)
Oct 8, 2025, 3:48 PM EDT
-1.42%
Market Cap7.88B
Revenue (ttm)17.27B
Net Income (ttm)497.94M
Shares Outn/a
EPS (ttm)1.08
PE Ratio15.82
Forward PE10.34
Dividend1.32 (7.77%)
Ex-Dividend DateMay 29, 2025
Volume291
Average Volume119
Open17.30
Previous Close17.55
Day's Range17.30 - 17.30
52-Week Range16.05 - 24.50
Beta0.89
RSI9.89
Earnings DateNov 4, 2025

About Evonik Industries AG

Evonik Industries AG produces and sells specialty chemicals in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America. It operates through Specialty Additives, Nutrition & Care, Smart Materials, and Technology & Infrastructure segments. The Specialty Additives segment offers additives for polyurethane foams; additives, matting agents, fumed silicas, and specialty resins for paints, coatings, and printing inks; isophorone and epoxy curing agents for coatings, adhesives, and composites; and pour-point depr... [Read more]

Sector Materials
Founded 1847
Employees 30,669
Stock Exchange OTCMKTS
Ticker Symbol EVKIF
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

Evonik Sees Persistently Weak Demand Until Year-end; Adjusts FY25 Outlook

(RTTNews) - Evonik Industries AG has adjusted the outlook for fiscal 2025. For 2025, Evonik had previously expected adjusted EBITDA to be between 2.0 billion and 2.3 billion euros, with the company mo...

13 days ago - Nasdaq

Evonik Industries reports Q2 results

2 months ago - Seeking Alpha

Evonik Industries AG (EVKIF) Q1 2025 Earnings Call Transcript

Evonik Industries AG (OTCPK:EVKIF) Q1 2025 Results Conference Call May 12, 2025 5:00 AM ETCompany ParticipantsChristian Kullmann - Chairman of the Executive...

5 months ago - Seeking Alpha

Evonik Industries reports Q1 results

5 months ago - Seeking Alpha

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven can...

10 months ago - Benzinga

Evonik Industries reports Q3 results

1 year ago - Seeking Alpha

Germany's Scholz calls for pragmatic approach to 'forever chemicals'

German Chancellor Olaf Scholz called for a pragmatic approach to toxic "forever chemicals" found in many household and everyday items during a visit to an Evonik site at the Marl Chemical Park on Mond...

1 year ago - Reuters

Evonik - I Continue To Be Long Here

Evonik has shown growth and strong performance in 3Q and 4Q23, with a 19% increase in share price since the last article. The company is undergoing a strategic realignment and investing in future tech...

1 year ago - Seeking Alpha

Evonik: Another Exit In A Low Margin Division

The company met its 2023 forecast despite a challenging environment, with positive performances in the Nutrition & Care division. Evonik confirmed its dividend per share thanks to a solid FCF and a su...

1 year ago - Seeking Alpha

Evonik to Cut 6% of Workforce

Evonik said it would cut up to 2,000 jobs by 2026, expecting cost reductions of around €400 million, after its fourth-quarter underlying earnings came in slightly below consensus forecasts.

1 year ago - WSJ

Evonik says recovery unlikely in 2024, plans 2,000 job cuts

German chemicals group Evonik Industries said on Monday it expected no signs of a recovery in 2024 and announced up to 2,000 job cuts worldwide by 2026 in a bid to cut costs.

1 year ago - Reuters

Evonik: The Reversal Could Be Significant, 'Buy'

Evonik Industries' position is currently volatile and uncertain, but I'm not worried. The company's 3Q23 results were above expectations, with positive cash generation and a confirmed adjusted EBITDA ...

1 year ago - Seeking Alpha

Germany's Economy Is in a Bad Slump. These 6 Stocks Could Rebound.

Look for companies that have been bearing the brunt of the pain to pull out stronger.

2 years ago - Barrons